Cargando…

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the East India cohort of the A(1)chieve study

BACKGROUND: The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. MATERIALS AND METHODS: Da...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahoo, Abhay Kumar, Das, Sambit, Prusty, Pitambar, Shankar, Anand, Guha, Shaibal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872899/
https://www.ncbi.nlm.nih.gov/pubmed/24404491
http://dx.doi.org/10.4103/2230-8210.122096
_version_ 1782297034794991616
author Sahoo, Abhay Kumar
Das, Sambit
Prusty, Pitambar
Shankar, Anand
Guha, Shaibal
author_facet Sahoo, Abhay Kumar
Das, Sambit
Prusty, Pitambar
Shankar, Anand
Guha, Shaibal
author_sort Sahoo, Abhay Kumar
collection PubMed
description BACKGROUND: The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. MATERIALS AND METHODS: Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from East India. RESULTS: A total of 2177 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (n=1605), insulin detemir (n=230), insulin aspart (n=233), basal insulin plus insulin aspart (n=49) and other insulin combinations (n=54). At baseline glycaemic control was poor for both insulin naïve (mean HbA1c: 8.9%) and insulin user (mean HbA1c: 9.1%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA1c (insulin naïve: -1.6%, insulin users: -1.6%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients. CONCLUSION: Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
format Online
Article
Text
id pubmed-3872899
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-38728992014-01-08 Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the East India cohort of the A(1)chieve study Sahoo, Abhay Kumar Das, Sambit Prusty, Pitambar Shankar, Anand Guha, Shaibal Indian J Endocrinol Metab Original Article BACKGROUND: The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. MATERIALS AND METHODS: Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from East India. RESULTS: A total of 2177 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (n=1605), insulin detemir (n=230), insulin aspart (n=233), basal insulin plus insulin aspart (n=49) and other insulin combinations (n=54). At baseline glycaemic control was poor for both insulin naïve (mean HbA1c: 8.9%) and insulin user (mean HbA1c: 9.1%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA1c (insulin naïve: -1.6%, insulin users: -1.6%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients. CONCLUSION: Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia. Medknow Publications & Media Pvt Ltd 2013-11 /pmc/articles/PMC3872899/ /pubmed/24404491 http://dx.doi.org/10.4103/2230-8210.122096 Text en Copyright: © Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Sahoo, Abhay Kumar
Das, Sambit
Prusty, Pitambar
Shankar, Anand
Guha, Shaibal
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the East India cohort of the A(1)chieve study
title Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the East India cohort of the A(1)chieve study
title_full Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the East India cohort of the A(1)chieve study
title_fullStr Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the East India cohort of the A(1)chieve study
title_full_unstemmed Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the East India cohort of the A(1)chieve study
title_short Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the East India cohort of the A(1)chieve study
title_sort clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: results from the east india cohort of the a(1)chieve study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872899/
https://www.ncbi.nlm.nih.gov/pubmed/24404491
http://dx.doi.org/10.4103/2230-8210.122096
work_keys_str_mv AT sahooabhaykumar clinicalexperiencewithinsulindetemirbiphasicinsulinaspartandinsulinaspartinpeoplewithtype2diabetesresultsfromtheeastindiacohortofthea1chievestudy
AT dassambit clinicalexperiencewithinsulindetemirbiphasicinsulinaspartandinsulinaspartinpeoplewithtype2diabetesresultsfromtheeastindiacohortofthea1chievestudy
AT prustypitambar clinicalexperiencewithinsulindetemirbiphasicinsulinaspartandinsulinaspartinpeoplewithtype2diabetesresultsfromtheeastindiacohortofthea1chievestudy
AT shankaranand clinicalexperiencewithinsulindetemirbiphasicinsulinaspartandinsulinaspartinpeoplewithtype2diabetesresultsfromtheeastindiacohortofthea1chievestudy
AT guhashaibal clinicalexperiencewithinsulindetemirbiphasicinsulinaspartandinsulinaspartinpeoplewithtype2diabetesresultsfromtheeastindiacohortofthea1chievestudy